C OSBORNE to Humans
This is a "connection" page, showing publications C OSBORNE has written about Humans.
Connection Strength
0.582
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.012
-
Circulating tumor DNA--ready for prime time? N Engl J Med. 2013 Mar 28; 368(13):1249-50.
Score: 0.011
-
Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4.
Score: 0.010
-
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Oncology (Williston Park). 2011 Dec; 25(14):1422-4, 1426.
Score: 0.010
-
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
Score: 0.009
-
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
Score: 0.009
-
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
Score: 0.007
-
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21.
Score: 0.007
-
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
Score: 0.007
-
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
Score: 0.007
-
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11.
Score: 0.006
-
Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7.
Score: 0.006
-
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
Score: 0.006
-
Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22.
Score: 0.006
-
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s.
Score: 0.006
-
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13.
Score: 0.006
-
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6.
Score: 0.006
-
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S.
Score: 0.006
-
Role of molecular and genetic markers in breast cancer treatment decisions. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):285s-287s.
Score: 0.006
-
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7.
Score: 0.006
-
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
Score: 0.006
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.005
-
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S.
Score: 0.005
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
Score: 0.005
-
Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
Score: 0.005
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.005
-
Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000 Sep; 18(17):3172-86.
Score: 0.005
-
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000 Mar 20; 89(2):111-7.
Score: 0.004
-
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
Score: 0.004
-
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
Score: 0.004
-
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):271-6.
Score: 0.004
-
Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26; 339(22):1609-18.
Score: 0.004
-
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res. 1998 May; 4(5):1263-6.
Score: 0.004
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.004
-
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar; 16(3):994-9.
Score: 0.004
-
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12.
Score: 0.004
-
Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51(3):227-38.
Score: 0.004
-
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501.
Score: 0.004
-
Oestrogen receptors and breast cancer. BMJ. 1997 Jun 28; 314(7098):1843-4.
Score: 0.004
-
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997 May; 15(5):1916-22.
Score: 0.004
-
Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74.
Score: 0.004
-
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. Semin Oncol. 1996 Aug; 23(4 Suppl 9):1.
Score: 0.003
-
Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). Cancer J Sci Am. 1996 May-Jun; 2(3):175-80.
Score: 0.003
-
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci. 1996 Apr 30; 784:325-35.
Score: 0.003
-
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51.
Score: 0.003
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
Score: 0.003
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.003
-
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
Score: 0.003
-
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85.
Score: 0.003
-
Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. Cancer. 1994 Aug 01; 74(3 Suppl):1135-8.
Score: 0.003
-
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 04; 86(9):705-12.
Score: 0.003
-
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
Score: 0.003
-
Translational research in the San Antonio breast cancer SPORE. Breast Cancer Res Treat. 1994; 32(1):1-4.
Score: 0.003
-
Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.
Score: 0.003
-
Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):13-8.
Score: 0.003
-
Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
Score: 0.003
-
Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
Score: 0.003
-
Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103.
Score: 0.003
-
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol. 1994 Jan; 5(1):43-7.
Score: 0.003
-
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec; 47(1-6):83-9.
Score: 0.003
-
Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum. 1993 Oct; 20(9):1415-9.
Score: 0.003
-
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep; 11(9):1710-6.
Score: 0.003
-
[An orientation toward caregiving]. TVZ. 1993 Jun 24; (12):393.
Score: 0.003
-
Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012 Nov 15; 131(10):2215-22.
Score: 0.003
-
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47-53.
Score: 0.003
-
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 01; 52(13):3636-41.
Score: 0.003
-
Prognostic factors in breast cancer. Semin Oncol. 1992 Jun; 19(3):244-53.
Score: 0.003
-
Prognostic factors for breast cancer: have they met their promise? J Clin Oncol. 1992 May; 10(5):679-82.
Score: 0.003
-
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb; 10(2):304-10.
Score: 0.003
-
Polypeptide growth factors: their potential value in the management of breast cancer patients. Cancer Treat Res. 1992; 60:315-29.
Score: 0.003
-
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
Score: 0.003
-
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer. 1992; 28(2-3):477-8.
Score: 0.003
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
Score: 0.003
-
Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S11-4.
Score: 0.002
-
Hematopoietic growth factors in breast cancer--overview. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S1-2.
Score: 0.002
-
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32.
Score: 0.002
-
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16; 83(20):1477-82.
Score: 0.002
-
A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5.
Score: 0.002
-
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
Score: 0.002
-
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res. 2011 Sep 01; 17(17):5559-61.
Score: 0.002
-
Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991 Jul; 9(7):1283-97.
Score: 0.002
-
Rapid identification of transfected plasmid expression vectors in cells by PCR. Biotechniques. 1991 Apr; 10(4):481-2, 484.
Score: 0.002
-
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb; 9(1):87-8.
Score: 0.002
-
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res. 1991; 53:289-304.
Score: 0.002
-
Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):805-9.
Score: 0.002
-
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76.
Score: 0.002
-
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990 Dec; 127(6):2679-86.
Score: 0.002
-
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
Score: 0.002
-
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990 Oct; 8(10):1675-82.
Score: 0.002
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul; 134(7):e48-72.
Score: 0.002
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 06; 134(6):907-22.
Score: 0.002
-
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 01; 28(16):2784-95.
Score: 0.002
-
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
Score: 0.002
-
Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990 Jan; 15(1):3-11.
Score: 0.002
-
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
Score: 0.002
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
Score: 0.002
-
Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
Score: 0.002
-
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15; 49(22):6237-41.
Score: 0.002
-
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov; 84(5):1418-23.
Score: 0.002
-
Megestrol acetate in breast cancer--a panel discussion. Breast Cancer Res Treat. 1989 Oct; 14(1):33-8.
Score: 0.002
-
DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst. 1989 Sep 20; 81(18):1344-5.
Score: 0.002
-
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
Score: 0.002
-
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
Score: 0.002
-
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs. 1989 Jul; 7(2-3):243-5.
Score: 0.002
-
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol. 1989 Jun; 7(6):710-7.
Score: 0.002
-
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62.
Score: 0.002
-
Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
Score: 0.002
-
Pain control in breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Jan; 13(1):5-15.
Score: 0.002
-
Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. Horm Res. 1989; 32 Suppl 1:238-41.
Score: 0.002
-
Adjuvant treatment of node-negative breast cancer. Tex Med. 1989 Jan; 85(1):32-6.
Score: 0.002
-
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol. 1988 Nov; 2(11):1064-9.
Score: 0.002
-
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988 Jul 15; 48(14):3898-904.
Score: 0.002
-
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9.
Score: 0.002
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.002
-
Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res Treat. 1987 Dec; 10(3):229-42.
Score: 0.002
-
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987 Aug; 23(8):1189-96.
Score: 0.002
-
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr; 30(2):113-25.
Score: 0.002
-
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61.
Score: 0.002
-
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21.
Score: 0.002
-
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006 Dec; 10(6):487-99.
Score: 0.002
-
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
Score: 0.002
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.002
-
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
Score: 0.002
-
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
Score: 0.002
-
Adjuvant chemotherapy. CA Cancer J Clin. 1986 Jan-Feb; 36(1):59-60.
Score: 0.002
-
Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr. 1986; (1):71-4.
Score: 0.002
-
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
Score: 0.002
-
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat. 2005 Dec; 94(3):205-11.
Score: 0.002
-
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
Score: 0.002
-
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35.
Score: 0.002
-
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol. 2006 Feb; 20(2):311-20.
Score: 0.002
-
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
Score: 0.002
-
Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985 Sep; 12(3):317-26.
Score: 0.002
-
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82.
Score: 0.002
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9.
Score: 0.002
-
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer. 2005 Jul; 12 Suppl 1:S113-7.
Score: 0.002
-
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
Score: 0.002
-
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat. 2005 Mar; 90(1):1-3.
Score: 0.002
-
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
Score: 0.002
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.002
-
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb; 45(2):584-90.
Score: 0.002
-
Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
Score: 0.002
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
Score: 0.002
-
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res Treat. 1985; 6(3):229-35.
Score: 0.002
-
Bisantrene, biological and clinical effects. Cancer Treat Rev. 1984 Dec; 11(4):285-8.
Score: 0.002
-
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9.
Score: 0.002
-
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
Score: 0.002
-
Hormone receptors in the management of breast cancer. Tex Med. 1984 Nov; 80(11):30-2.
Score: 0.002
-
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004 Sep 01; 10(17):5670-6.
Score: 0.002
-
Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res. 1984 Aug; 44(8):3570-5.
Score: 0.001
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.001
-
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr; 44(4):1433-9.
Score: 0.001
-
Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep. 1984 Feb; 68(2):357-60.
Score: 0.001
-
Spreading the word, but not too thinly. Lancet. 2004 Jan 10; 363(9403):165-6.
Score: 0.001
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.001
-
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983 Dec; 67(12):1133-5.
Score: 0.001
-
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
Score: 0.001
-
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983 Aug; 43(8):3583-5.
Score: 0.001
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
Score: 0.001
-
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26.
Score: 0.001
-
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003 Jun; 39(9):1228-33.
Score: 0.001
-
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
Score: 0.001
-
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9.
Score: 0.001
-
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May; 79(2):207-11.
Score: 0.001
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.001
-
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9.
Score: 0.001
-
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
Score: 0.001
-
Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther. 2002 Dec; 6(6):783-92.
Score: 0.001
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.001
-
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol. 1982; 8(3):261-5.
Score: 0.001
-
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
Score: 0.001
-
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001 Aug 01; 61(15):5771-7.
Score: 0.001
-
Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 2001 May 01; 61(9):3578-80.
Score: 0.001
-
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest. 1981 Apr; 67(4):943-51.
Score: 0.001
-
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 2001 Mar 01; 61(5):2320-7.
Score: 0.001
-
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer. 2001 Feb; 84(4):493-8.
Score: 0.001
-
Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol. 1981; 138:377-85.
Score: 0.001
-
Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981; 1(2):121-3.
Score: 0.001
-
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl):2884-8.
Score: 0.001
-
Modern approaches to the treatment of breast cancer. Blood. 1980 Nov; 56(5):745-52.
Score: 0.001
-
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res. 2000 Sep; 6(9):3788-96.
Score: 0.001
-
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15; 89(4):817-25.
Score: 0.001
-
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res. 1980 Jul; 40(7):2361-6.
Score: 0.001
-
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood. 1980 Jul; 56(1):98-103.
Score: 0.001
-
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
Score: 0.001
-
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
Score: 0.001
-
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
Score: 0.001
-
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
Score: 0.001
-
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res. 1979 Jul; 39(7 Pt 1):2422-8.
Score: 0.001
-
Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979 May; 130(5):401-7.
Score: 0.001
-
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
Score: 0.001
-
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8.
Score: 0.001
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May; 17(5):1474-81.
Score: 0.001
-
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem. 1999 Apr 16; 274(16):11334-8.
Score: 0.001
-
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
Score: 0.001
-
The use of stero?d hormone receptors in the treatment of human breast cancer: a review. Bull Cancer. 1979; 66(3):203-9.
Score: 0.001
-
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol. 1998 Nov; 16(11):3486-92.
Score: 0.001
-
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. Breast Cancer Res Treat. 1998 Sep; 51(2):169-81.
Score: 0.001
-
Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am. 1978 Aug; 58(4):777-88.
Score: 0.001
-
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91.
Score: 0.001
-
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998 May 06; 90(9):697-703.
Score: 0.001
-
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
Score: 0.001
-
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May; 16(5):1669-76.
Score: 0.001
-
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
Score: 0.001
-
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
Score: 0.001
-
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res. 1978 Jan; 38(1):94-102.
Score: 0.001
-
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
Score: 0.001
-
Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81.
Score: 0.001
-
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
Score: 0.001
-
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997 Sep 01; 57(17):3723-7.
Score: 0.001
-
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
Score: 0.001
-
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
Score: 0.001
-
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600.
Score: 0.001
-
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A. 1976 Dec; 73(12):4536-40.
Score: 0.001
-
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
Score: 0.001
-
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
Score: 0.001
-
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71.
Score: 0.001
-
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
Score: 0.001
-
Aberrant subcellular localization of BRCA1 in breast cancer. Science. 1995 Nov 03; 270(5237):789-91.
Score: 0.001
-
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
Score: 0.001
-
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995 Aug 16; 87(16):1254-6.
Score: 0.001
-
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res. 1995 Aug; 1(8):921-32.
Score: 0.001
-
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar; 33(3):199-207.
Score: 0.001
-
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res. 1994 Oct 15; 54(20):5357-62.
Score: 0.001
-
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994 Mar 15; 13(6):1331-40.
Score: 0.001
-
Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):5-12.
Score: 0.001
-
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1994; 12(2):129-32.
Score: 0.001
-
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
Score: 0.001
-
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
Score: 0.001
-
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
Score: 0.001
-
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep; 23(9):974-9.
Score: 0.001
-
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol. 1992 Jun; 10(6):990-4.
Score: 0.001
-
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol. 1992 Mar; 10(3):428-32.
Score: 0.001
-
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
Score: 0.001
-
Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104.
Score: 0.001
-
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug; 4(8):979-84.
Score: 0.001
-
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90.
Score: 0.001
-
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989; 32 Suppl 1:221-2.
Score: 0.001
-
The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat. 1988 Oct; 12(2):159-66.
Score: 0.001
-
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res. 1988 Sep 01; 48(17):5023-8.
Score: 0.000
-
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol. 1987 May; 23(5):545-51.
Score: 0.000
-
Resistance to endocrine therapy. A panel discussion. Breast Cancer Res Treat. 1987; 9(3):165-73.
Score: 0.000
-
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan; 5(1):55-61.
Score: 0.000
-
The use of restriction fragment polymorphisms to identify the cell line MCF-7. Breast Cancer Res Treat. 1986; 8(1):29-34.
Score: 0.000
-
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem. 1985 Dec; 23(6B):1151-4.
Score: 0.000
-
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM. World J Surg. 1985 Oct; 9(5):719-22.
Score: 0.000
-
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg. 1985 Oct; 9(5):723-7.
Score: 0.000
-
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
Score: 0.000
-
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9.
Score: 0.000
-
An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983 Aug 01; 52(3):393-8.
Score: 0.000
-
Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1983; 3(3):279-85.
Score: 0.000
-
Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs. 1983; 1(1):85-8.
Score: 0.000
-
Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan; 43(1):413-6.
Score: 0.000
-
Steroid hormone receptors and carcinoma of the breast. Am J Physiol. 1982 Aug; 243(2):E99-102.
Score: 0.000
-
Histologic progression in non-Hodgkin's lymphoma. Blood. 1982 Feb; 59(2):258-64.
Score: 0.000
-
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells (1981). 1982; 2(1):34-44.
Score: 0.000
-
Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1981; 1(1):37-41.
Score: 0.000
-
Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat. 1981; 1(2):131-4.
Score: 0.000
-
Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat. 1981; 1(2):141-8.
Score: 0.000
-
Steroid hormone receptors in the management of human breast cancer. Ann Clin Res. 1980 Oct; 12(5):202-7.
Score: 0.000
-
Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980 Jul; 9(2):361-8.
Score: 0.000
-
Breast cancer mortality and diet in the United States. Cancer Res. 1979 Sep; 39(9):3628-37.
Score: 0.000
-
Insulin stimulation of fatty acid synthesis in human breast cancer cells. J Natl Cancer Inst. 1977 Jun; 58(6):1591-3.
Score: 0.000
-
In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9.
Score: 0.000
-
Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35.
Score: 0.000